Read by QxMD icon Read

Journal of Child and Adolescent Psychopharmacology

Oliver Scholle, Tobias Banaschewski, Dirk Enders, Edeltraut Garbe, Oliver Riedel
OBJECTIVE: Children and adolescents with attention-deficit/hyperactivity disorder (ADHD) frequently have comorbidities that are potential indications for antipsychotics (APs). Some studies have suggested that the combined use of methylphenidate (MPH) and APs is increasing in this population group. Longitudinal analyses and in-depth investigations on the substance level are lacking. This study aimed to estimate the cumulative proportion of concomitant AP/MPH use in children and adolescents with ADHD over a follow-up of up to 9 years and to describe patient characteristics stratified by specific AP drug...
May 16, 2018: Journal of Child and Adolescent Psychopharmacology
Yvette E Lentferink, Ewoudt M W van de Garde, Catherijne A J Knibbe, Marja M J van der Vorst
OBJECTIVES: Attention-deficit/hyperactivity disorder (ADHD) is often treated with psychostimulants. Psychostimulants' adverse effects on body mass index standard deviation score (BMI-sds) and height in children/adolescents with ADHD have been reported. However, literature is inconsistent, and it is unclear whether the observed effects are dosage- and/or BMI-dependent. Therefore, the aim of this retrospective observational study is to evaluate the influence of psychostimulants on BMI-sds and height-sds in a pediatric cohort with ADHD from an outpatient clinic, and to study the correlation between psychostimulant dosage and BMI-sds and height-sds change...
May 16, 2018: Journal of Child and Adolescent Psychopharmacology
Louis T van Zyl, Sharon A Chung, Azmeh Shahid, Colin M Shapiro
OBJECTIVE: Parasomnias are common in childhood but there is no established treatment for parasomnias. The aim of this study was to (1) report on the outcome of using L-tryptophan to manage parasomnias in children and (2) examine sleep architecture and subjective psychological/sleep symptoms in children with parasomnia. METHOD: A retrospective analysis was conducted of charts of children (3-18 years old) who underwent polysomnographic testing and were diagnosed with primary parasomnia...
May 9, 2018: Journal of Child and Adolescent Psychopharmacology
Amalia Londono Tobon, Margot O Reed, Jerome H Taylor, Michael H Bloch
OBJECTIVE: School refusal is an important pediatric problem with significant negative short- and long-term outcomes. Specific psychosocial treatments appear effective in reducing school refusal, but many children do not respond to these treatments. Although systematic reviews have examined the efficacy of psychological interventions for school refusal, no systematic reviews on pharmacological interventions exist. METHODS: We conducted a comprehensive literature search of MEDLINE, PsycINFO, Scopus, and Embase for randomized controlled trials (RCTs) or quasi-experimental pharmacologic trials in children and adolescents with school refusal reported in English or Spanish until July 1, 2017...
May 9, 2018: Journal of Child and Adolescent Psychopharmacology
Betül Akbas, Omer Faruk Akca
No abstract text is available yet for this article.
May 1, 2018: Journal of Child and Adolescent Psychopharmacology
Drew E Winters, Sadaaki Fukui, Ellen Leibenluft, Leslie A Hulvershorn
OBJECTIVE: The purpose of this open-label study was to examine the effects of long-acting methylphenidate (MPH) treatment on irritability and related emotional symptoms associated with disruptive mood dysregulation disorder (DMDD) in youth with comorbid attention-deficit/hyperactivity disorder (ADHD). METHODS: The sample included 22 medication-free male and female subjects (ages 9-15) who met criteria for both DMDD and ADHD. Participants underwent a 4-week trial of long-acting MPH treatment (Concerta® ), with weekly dosing increases until a therapeutic dose was reached...
April 30, 2018: Journal of Child and Adolescent Psychopharmacology
L Eugene Arnold, Nicole Ober, Michael G Aman, Benjamin Handen, Tristram Smith, Xueliang Pan, Susan L Hyman, Jill Hollway, Luc Lecavalier, Kristin Page, Robert Rice
OBJECTIVE: To examine status of children with autism spectrum disorder (ASD) 10 months after a 34-week clinical trial of atomoxetine (ATX) and parent training (PT). METHODS: In a 2 × 2 design, 128 children with ASD and attention-deficit/hyperactivity disorder (ADHD) were randomly assigned ATX, PT+placebo, PT+ATX, or placebo alone. PT was weekly for 10 weeks, and then monthly. ATX/placebo was titrated over 6 weeks [≤1.8 mg/kg/d], and then maintained until week 10...
April 25, 2018: Journal of Child and Adolescent Psychopharmacology
Hyo-Won Kim, Eun-Jin Park, Ji-Hoon Kim, Vitharon Boon-Yasidhi, Jariya Tarugsa, Alexis Reyes, Stella Manalo, Yoo-Sook Joung
OBJECTIVES: We investigated the effectiveness and tolerability of aripiprazole in the treatment of irritability in Asian children and adolescents (6-17 years) with autistic disorder in a 12-week, multinational, multicenter, open-label study. METHODS: Sixty-seven subjects (10.0 ± 3.1 years old, 52 boys) were enrolled and treated with flexibly dosed aripiprazole for 12 weeks (mean dose, 5.1 ± 2.5 mg; range 2-15 mg). RESULTS: Aripiprazole significantly reduced the mean caregiver-rated scores for the Irritability, Lethargy/Social Withdrawal, Stereotypy, Hyperactivity, and Inappropriate Speech subscales of the Aberrant Behavior Checklist from baseline to week 12 (p < 0...
April 24, 2018: Journal of Child and Adolescent Psychopharmacology
Fadi Maalouf, Rinad Bakhti, Hani Tamim, Safa Shehab, David Brent
OBJECTIVES: Numerous studies have suggested cognitive deficits as consistently associated with adolescent depression. No study to date, however, has assessed neurocognitive predictors of selective serotonin reuptake inhibitor (SSRI) treatment response in adolescents with depression. This study examined neurocognitive tasks at baseline as predictors of clinical improvement with SSRI treatment (fluoxetine) at week 6 and 12 in an adolescent population. METHODS: Adolescents with depression were recruited from a child and adolescent psychiatry outpatient clinic at a university medical center...
April 13, 2018: Journal of Child and Adolescent Psychopharmacology
Jennifer C Wolff, Elisabeth A Frazier, Sarah L Weatherall, Alysha D Thompson, Richard T Liu, Jeffrey I Hunt
OBJECTIVES: This study evaluated the feasibility and initial efficacy of an empirically informed psychosocial intervention on an adolescent psychiatric inpatient unit. METHODS: Data were obtained for 463 adolescents 12-16 years of age on a psychiatric inpatient unit. Information collected included demographics, psychiatric diagnoses, length of inpatient stay, completion of four treatment modules, rehospitalizations, and emergency room visits during 12 months after discharge from index admission...
April 12, 2018: Journal of Child and Adolescent Psychopharmacology
Gabrielle E Hodgins, Samantha B Saltz, Eric P Gibbs, Rolando Gonzalez, Judith Regan, Charles Nemeroff
OBJECTIVES: Iatrogenic steroid-induced psychosis is a rare but serious adverse side effect seen largely in the adult population that less commonly affects children and adolescents. Given the significant distress steroid-induced psychosis may cause, recommendations are needed for effective management. Here we conducted a systematic review of the literature and report a new case of steroid-induced psychosis in a 12-year-old patient. METHODS: We performed a systematic search using Embase, PubMed, Scopus, and PsychInfo...
April 11, 2018: Journal of Child and Adolescent Psychopharmacology
Çağla Çelikkol, Ayhan Bilgiç
No abstract text is available yet for this article.
April 9, 2018: Journal of Child and Adolescent Psychopharmacology
Jeffrey R Strawn, Paul E Croarkin
No abstract text is available yet for this article.
April 5, 2018: Journal of Child and Adolescent Psychopharmacology
Michael G Aman, Jill A Hollway, Jeremy Veenstra-VanderWeele, Benjamin L Handen, Kevin B Sanders, James Chan, Eric Macklin, L Eugene Arnold, Taylor Wong, Cassandra Newsom, Rianne Hastie Adams, Sarah Marler, Naomi Peleg, Evdokia A Anagnostou
OBJECTIVES: Studies in humans and rodents suggest that metformin, a medicine typically used to treat type 2 diabetes, may have beneficial effects on memory. We sought to determine whether metformin improved spatial or verbal memory in children with autism spectrum disorder (ASD) and overweight associated with atypical antipsychotic use. METHODS: We studied the effects of metformin (Riomet® ) concentrate on spatial and verbal memory in 51 youth with ASD, ages 6 through 17 years, who were taking atypical antipsychotic medications, had gained significant weight, and were enrolled in a trial of metformin for weight management...
April 5, 2018: Journal of Child and Adolescent Psychopharmacology
Keonie Moore
No abstract text is available yet for this article.
March 16, 2018: Journal of Child and Adolescent Psychopharmacology
Sanna-Mari Tähkäpää, Leena Saastamoinen, Marja Airaksinen, Annamari Tuulio-Henriksson, Terhi Aalto-Setälä, Terhi Kurko
OBJECTIVE: Patterns of benzodiazepine (BZD) use and long-term use among young adults are not well known. Our aim was to study trends in BZD use and long-term use among 18-25-year-old young adults by gender and active substance in a nationwide retrospective longitudinal register-based setting. METHODS: All Finns aged 18-25 years with reimbursed purchases of BZDs in 2006-2014 recorded to the Finnish Prescription Register were included. Annual prevalence rates of BZD use and long-term use among young adults were reported overall, according to gender, drug group (anxiolytic or hypnotic), and active substance...
March 14, 2018: Journal of Child and Adolescent Psychopharmacology
Sanne M Kloosterboer, Catharina C M Schuiling-Veninga, Jens H J Bos, Luuk J Kalverdijk, Birgit C P Koch, Gwen C Dieleman, Manon H J Hillegers, Bram Dierckx
OBJECTIVES: The use of antipsychotic drugs by youth is associated with serious side effects, especially when prescribed in higher dosages and for a longer period. Despite this, little is known about recent trends in the dosages and duration of use of antipsychotic drugs in children and adolescents. The aim of this study was to describe trends in prevalence, incidence, dosages, duration of use, and preceding psychotropic medication in Dutch youth who had been prescribed antipsychotic drugs from 2005 to 2015...
March 13, 2018: Journal of Child and Adolescent Psychopharmacology
Bo Kyum Yang, Mehmet Burcu, Daniel J Safer, Alison M Trinkoff, Julie M Zito
OBJECTIVE: To describe psychotropic medication prescribing practices of nurse practitioners (NP) and physicians for Medicaid-insured youths in 2012-2014 in a mid-Atlantic state where NP independent prescribing is authorized. METHOD: From annual computerized administrative claims data in a mid-Atlantic state, we analyzed 1,034,798 dispensed psychotropic medications prescribed by NPs and physicians for 61,526 continuously enrolled Medicaid-insured youths aged 2-17 years...
March 13, 2018: Journal of Child and Adolescent Psychopharmacology
Sharon B Wigal, Ann Childress, Sally A Berry, Heidi W Belden, Phillip Chappell, Dalia B Wajsbrot, Praneeta Nagraj, Richat Abbas, Donna Palumbo
OBJECTIVE: To examine methylphenidate extended-release chewable tablets (MPH ERCT) dose patterns, attention-deficit/hyperactivity disorder (ADHD) symptom scores, and safety during the 6-week, open-label (OL) dose-optimization period of a phase 3, laboratory classroom study. METHODS: Boys and girls (6-12 years) diagnosed with ADHD were enrolled. MPH ERCT was initiated at 20 mg/day; participants were titrated in 10-20 mg/day increments weekly based on efficacy and tolerability (maximum dose, 60 mg/day)...
March 13, 2018: Journal of Child and Adolescent Psychopharmacology
Hankil Lee, Dong-Ho Song, Euna Han, Hye-Young Kang
OBJECTIVE: This population-based epidemiologic study aimed to analyze the prevalence and trends of atypical antipsychotic (AAP) use and identify factors associated with AAP prescribing among children and adolescents in Korea. METHODS: Using the Health Insurance Review and Assessment Service-Pediatric Patients Sample data between 2010 and 2014, we assessed the prevalence of and secular trends in AAP use; utilization of individual AAP drug based on the type of healthcare services, healthcare institutions, and health security programs; and factors associated with AAP use...
March 12, 2018: Journal of Child and Adolescent Psychopharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"